| ABSTRACT Objective: To understand the characteristics of monosialotetrahexosyl ganglioside(GM1) related Guillain Barre syndrome (GBS), and provide reference for clinical safe drug usage. Methods:Five cases of GBS caused by intravenous injection of GM1 were reported in our hospital. The case reports of GBS related to ganglioside in domestic academic journals from January 2002 to December 2018 were retrieved. The literature cases were screened and merged with in hospital cases. Gender, age, original disease, underlying disease, history of precursor infection, dosage and course of treatment, combined use of drugs, initial symptoms of adverse reactions, main manifestations, weakening or disappearance of bilateral tendon reflex, occurrence time of adverse reactions, average peak time of disease, laboratory examination, severity, etc. Data of treatment and outcome were collected and analyzed. Results:A total of 22 cases were enrolled, 21 males and 1 females, 50.00% of them were 50 60 years old. GM1 associated GBS occured mostly in patients with cerebral hemorrhage, cerebral infarction and traumatic brain injury. 31.82% of the patients had autoimmune related diseases. There was no clear correlation between the dosage, course of treatment and the severity of adverse reactions of gangliosides. GM1 associated GBS mostly starts with decreased muscle strength and muscle tone. All cases were characterized by limb weakness, and most of them were accompanied by cranial nerve involvement, conscious disturbance, autonomic nervous dysfunction, sensory and respiratory dysfunction. Adverse reactions mostly occurred in 8 14 days and peaked in 1 3 days. The degree of limb paralysis was serious and the clinical outcome was poor. Conclusion:GM1 may lead to GBS. In clinical application, we should strictly grasp the indications of medication, strengthen medication monitoring, stop medication in time and use intravenous human immunoglobulin after diagnosis of GBS, so as to avoid the occurrence of adverse reactions and further aggravation. |
